Stein Steven H, an insider at Incyte Corp (INCY), purchased 104,080 shares at a price of $83.83 per share on November 4, 2025, amounting to a total transaction value of $8.73 million. Following this acquisition, Stein holds 104,080 shares of the company.
Incyte Corp is a biopharmaceutical company engaged in the discovery, development, and commercialization of proprietary therapeutics. Headquartered in Wilmington, Delaware, the firm has a market capitalization of $20.5 billion and employs 2,617 full-time staff. The company's therapeutic areas include Hematology/Oncology and Inflammation and Autoimmunity, with several products such as JAKAFI (ruxolitinib) and MONJUVI (tafasitamab).
The move underscores potential confidence in the company's future, as insider buying often reflects executives' perspectives on their firm's prospects. However, investors should consider a broader context of insider activities and not base decisions solely on individual transactions. Patterns of buying across multiple insiders may provide more comprehensive insights.
Incyte's upcoming earnings are scheduled for July 26, 2026, with an estimated EPS of $1.68 and revenue of $1.3 billion. The company's P/E ratio stands at 17.24, with a trailing EPS of 5.91.